Glutamic Acid

Glutamic Acid

SCHEMBL2680237

NCC(=O)OCC(O)CO.N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 2/20 0.53
GRM6 O15303 2/20 0.53
GRM7 Q14831 2/20 0.53
GRM4 Q14833 2/20 0.53
GSR P00390 2/20 0.53
GRIN2D O15399 1/20 0.53
GRIN3B O60391 1/20 0.53
CYP1A2 P05177 1/20 0.53
GRIK1 P39086 1/20 0.53
GRM5 P41594 1/20 0.53
GRIA1 P42261 1/20 0.53
GRIA2 P42262 1/20 0.53
GRIA3 P42263 1/20 0.53
SLC1A3 P43003 1/20 0.53
SLC1A2 P43004 1/20 0.53
SLC1A1 P43005 1/20 0.53
GRIA4 P48058 1/20 0.53
GRIN1 Q05586 1/20 0.53
GRIN2A Q12879 1/20 0.53
GRIK2 Q13002 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamic Acid SCHEMBL3072013 0.86 GRM8 (0.62) GRM8GRM6GRM7GRM4GSR
SCHEMBL7197020 0.86 KMT2A (0.50) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL2680239 0.82 GRM8 (0.67) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL9617054 0.82 GRM8 (0.49) GRM8GRM6GRM7GRM4GSR
SCHEMBL20489390 0.81 GRM8 (0.48) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL28630462 0.81 GRM8 (0.75) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL17962756 0.81 GRM8 (0.75) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL28870726 0.81 GRM8 (0.75) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL9500095 0.81 GRM8 (0.75) GRM8GRM6GRM7GRM4GSR
SCHEMBL351117 0.80 LMNA (0.52) KMT2AKDM4EDUSP3MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993117-B2 Devices with multiple surface functionality THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2015-03-31 US disclosed
US-20120121661-A1 DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2012-05-17 US disclosed
US-20120114935-A1 DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2012-05-10 US disclosed
US-7507483-B2 Enhanced bonding layers on native oxide surfaces NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-03-24 US disclosed
US-20060194008-A1 Devices with multiple surface functionality PRINCETON UNIVERSITY (US) 2006-08-31 US disclosed
US-20040023048-A1 Enhanced bonding layers on native oxide surfaces NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121661-A1 DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY PHOSPHO1, CD44, SELP GRM8 1521/4885GRM6 458/4885GRM7 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.